The contract development and manufacturing (CDMO) expanded construction at its WuXi city facility by 240,000 square-feet.
WuXi Biologics began building the 200,000 square-foot plant last June for $20m (€17.2m) to enhance technical capabilities and commercial manufacturing capacities for the bioconjugation field.
According to WuXi Biologics, bioconjugates, such as antibody-drug conjugates (ADCs), are a growing field in biopharma and create opportunities to treat cancers and demand for their manufacture is increasing.
A spokesperson for WuXi Biologics told us that with the addition of this expanded plant, the company will provide conjugation approaches and chemistry, and scale-up the manufacture of payload, linker, and antibodies.
The biopharma company will be able to provide commercial manufacturing for ADCs drug substance and drug product.
Chris Chen, CEO of WuXi Biologics, said in a statement that it will use its one-stop service platform for antibody, bioconjugation drug substance, and drug product.
Currently, more than 20 ADCs are being developed by WuXi Biologics and the company advanced 11 of the projects to investigational new drug (IND) filings.
The center is expected to initiate good manufacturing practice (GMP) manufacturing later in 2019.
